Physician profile
Branislav Romanic
NPI 1649239153
$3,647.85
in general payments reported to CMS, 2019-2025
25 companies · $907 in 2025
The $907 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $331 · 2021: $306 · 2022: $64.10 · 2023: $465 · 2024: $791 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153 · Education: $9.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.72 |
| Education | $9.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $922.34 | 2021-2025 | Velphoro, Velphoro |
| Amgen INC. | $607.76 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Aurinia Pharma U.S., INC. | $251.89 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $232.67 | 2019-2021 | |
| Glaxosmithkline, LLC. | $198.22 | 2019-2025 | Benlysta, Nucala |
| Ani Pharmaceuticals, INC. | $167.72 | 2023-2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $161.88 | 2019-2020 | |
| Janssen Biotech, INC. | $157.99 | 2019-2025 | Tremfya |
| Abbvie INC. | $136.31 | 2024-2025 | |
| Vifor Pharma, INC. | $110.06 | 2019-2021 | |
| Medtronic, INC. | $106.43 | 2023 | Intellis Adaptivestim |
| Mallinckrodt Enterprises LLC | $101.32 | 2019 | |
| Mallinckrodt Hospital Products INC. | $85.99 | 2020-2025 | Acthar |
| Ucb, INC. | $61.00 | 2023-2025 | Bimzelx, Cimzia |
| Sobi, INC | $51.92 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $49.86 | 2019 | |
| Fresenius Kabi USA, LLC | $40.77 | 2023-2024 | Idacio |
| Radius Health, INC. | $39.09 | 2024-2025 | Tymlos |
| Otsuka America Pharmaceutical, INC. | $38.91 | 2019 | |
| Alexion Pharmaceuticals, INC. | $38.90 | 2020-2023 | Strensiq |
| Horizon Therapeutics Plc | $26.56 | 2023 | Krystexxa |
| Antares Pharma, INC. | $20.25 | 2019 | |
| Akebia Therapeutics INC | $18.28 | 2019 | |
| Shire North American Group INC | $12.10 | 2019 | |
| Travere Therapeutics, INC. | $9.63 | 2023-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Branislav Romanic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.